VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling. In diabetic mice, VGX-1027 decreases synthesis of pro-inflammatory cytokines and improves glomerulosclerosis. In other animal models, this compound inhibits antigen presentation, preventing the development of systemic lupus erythmatosus (SLE), increases survival rates and improving overall pathology.
| Cas No. | 6501-72-0 |
|---|---|
| Purity | ≥98% |
| Formula | C11H11NO3 |
| Formula Wt. | 205.21 |
| IUPAC Name | (3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid |
| Synonym | GIT27 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | V2792 Info Sheet PDF |
|---|---|
| Brochures | TLR Flyer |
Fagone P, Muthumani K, Mangano K, et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology. 2014 Aug;142(4):594-602. PMID: 24527796.
Cha JJ, Hyun YY, Lee MH, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. 2013 Jun;154(6):2144-55. PMID: 23568555.
Stojanovic I, Cuzzocrea S, Mangano K, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immunol. 2007 Jun;123(3):311-23. PMID: 17449326.
